Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08
(Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients
Who Have Chronic Hepatitis Genotype 1.